MRNA · News · 20261112N

Revenue Performance and Mix

Moderna, Inc. · 2026-11-12 · Importance 78 · Surprise 84

Moderna raised its 2026 revenue growth forecast to 15%–25%. A third-party recap attributed the improvement mainly to stronger international sales of its COVID-19 vaccine in the third quarter of 2026. The reports did not provide revenue amounts by product or geography.

Key facts